Experts weigh in on the various legislative pathways

WASHINGTON — Having already submitted two congressionally mandated reports on cannabidiol (CBD), it’s looking less and less likely that the U.S. Food and Drug Administration (FDA) will release the long-awaited regulations that would provide a pathway for ingestible products. Leaving many in the industry to question if Congress might be able to speed things up.

While several representatives have sent official letters to the FDA in support of CBD, attorney Jonathan Havens says the agency is unlikely to do a complete 180.

“I haven’t yet seen FDA say that just because they’re getting pressure from Congress and stakeholders, they’ll dispense with their normal review and ignore the data gaps that the Agency perceives to exist,” he told CSP Daily News. Havens co-chairs both the Cannabis Law and Food, Beverage and Agribusiness practices at Saul Ewing Arnstein & Lehr LLP and previously served as a regulatory counsel at the FDA.

“I don’t see that legislation passing this year, particularly given the focus of Washington on the pandemic, economy and election,” said Patrick Goggin, a senior attorney specializing in cannabis at San Francisco-based Hoban Law Group.

Read the full article on CSP Daily News